Detalhe da pesquisa
1.
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.
Lancet
; 402(10400): 451-463, 2023 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37423228
2.
Symptom relief, prognostic factors, and outcome in patients receiving urgent radiation therapy for superior vena cava syndrome : A single-center retrospective analysis of 21 years' practice.
Strahlenther Onkol
; 198(12): 1072-1081, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35552767
3.
Smoking cessation by combined medication and counselling: a feasibility study in lung cancer patients.
BMC Pulm Med
; 22(1): 252, 2022 Jun 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-35761222
4.
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
Lancet Oncol
; 20(7): 924-937, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31122901
5.
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Lancet
; 389(10066): 255-265, 2017 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-27979383
6.
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Lancet
; 387(10030): 1837-46, 2016 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-26970723
7.
Treatment of limited disease small cell lung cancer: the multidisciplinary team.
Eur Respir J
; 50(2)2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28838979
8.
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.
J Clin Oncol
; 42(3): 324-335, 2024 Jan 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37976444
9.
Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1-High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer.
J Thorac Oncol
; 19(5): 803-817, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38096950
10.
Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany.
Eur J Cancer
; 201: 113911, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38377774
11.
Real-World Progression-Free Survival as an Endpoint in Lung Cancer: Replicating Atezolizumab and Docetaxel Arms of the OAK Trial Using Real-World Data.
Clin Pharmacol Ther
; 114(6): 1313-1322, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37696652
12.
NTRK Gene Fusions in Non-Small-Cell Lung Cancer: Real-World Screening Data of 1068 Unselected Patients.
Cancers (Basel)
; 15(11)2023 May 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37296928
13.
Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.
Clin Lung Cancer
; 23(1): 21-33, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34226144
14.
Update on recent key publications in lung oncology: picking up speed.
Eur Respir Rev
; 30(161)2021 Sep 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34261741
15.
Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV.
Transl Lung Cancer Res
; 10(7): 3093-3105, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34430350
16.
Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT).
Lung Cancer
; 160: 17-27, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34371299
17.
Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel.
J Immunother Cancer
; 9(3)2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33737340
18.
Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials.
J Thorac Oncol
; 16(1): 140-150, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33166718
19.
Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).
Lung Cancer
; 152: 174-184, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33358484
20.
Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program.
Ther Adv Med Oncol
; 13: 17588359211019675, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34178121